Business Context and Reporting Period
This Form 8-K is filed by Second Sight Medical Products, Inc. (trading symbol: EYES) for the reporting period ending March 26, 2021. The filing primarily addresses a change in executive leadership following a capital raise.
Key Financial Metrics
The filing reports the completion of a private placement raising $27.9 million on March 26, 2021. The document does not provide specific values for revenue, profit, operating cash flow, margins, total debt, or liquidity ratios beyond the proceeds from this specific financing event.
Material Changes
- Executive Leadership: Matthew Pfeffer stepped down as Acting Chief Executive Officer immediately following the close of the private placement.
- Succession: The Board of Directors appointed Scott Dunbar as the new Acting CEO. Mr. Dunbar had previously served as Senior Patent Counsel and Compliance Officer for approximately 19 years.
- Board Composition: Matthew Pfeffer remains on the Board of Directors as an independent director. The filing notes that under NASDAQ rules, his interim employment as an executive officer does not disqualify his independence status provided the interim period does not exceed one year.
Guidance, Outlook, and Risks
The filing does not contain forward-looking guidance, financial outlook, or specific risk factors beyond the standard disclosure of the leadership transition. The change in CEO is presented as a completed event effective immediately after the capital raise.
Investor Verification Checklist
- Verify the final closing details and use of proceeds for the $27.9 million private placement.
- Confirm Scott Dunbar's full compensation package and any new employment agreements.
- Review the press release (Exhibit 99.1) for additional strategic context regarding the leadership change.
- Monitor future filings to ensure Matthew Pfeffer's interim role does not exceed the one-year threshold for maintaining independent director status.